Xalkori (Crizotinib) Crizotinib 200mg – ALK/ROS1+ NSCLC, ALCL, and IMT

XALKORI (crizotinib) is indicated for the treatment of certain types of cancer that present specific genetic alterations involving the ALK or ROS1 genes.
It is used in adults with metastatic non-small cell lung cancer (NSCLC) that is ALK- or ROS1-positive.
It is also indicated for pediatric patients (from 1 year of age) and young adults with systemic, ALK-positive anaplastic large cell lymphoma (ALCL), who have relapsed or are refractory.
Additionally, it is used in adult and pediatric patients (from 1 year of age) with ALK-positive inflammatory myofibroblastic tumor (IMT) that is unresectable, recurrent, or refractory.